Monday, December 03, 2018 8:29:11 AM
Huge fan of the products itself. I feel bad for Andy to a certain degree, then when I look at this past opportunity, and it simply failed in my opinion because we didn't have proper representation for this opportunity. But after this mishap, no matter what anybody else thinks, Andy should now realize that by not bringing GP to the party, this opportunity never had a chance. FDA has always had a horrible reputation of having BIG PHARMA LIVING IN THEIR POCKET! He needs to to step down immediately.
Is it too late to contact GP and have them review everything that went down. If I were the new management coming in, I would definitely have them review this. Could they possibly revive this denial by having an adult rebuttals for their BS arguement men vs women efficacy.
This product will become SOC with the right team in place, THE PRODUCT WORKS GREAT!
My comments above are simply my opinion and nothing more.
I'm enthusiastic at times however I am NOT a professional trader.
Please contact a financial consultant for investment advice.
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM